Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed thyroid carcinoma, including 1 of the following subtypes:
• •* Papillary
• •* Follicular
• •* Hurthle cell
• •* Insular
• •Assessable disease, defined by at least 1 of the following:
• •* Metastatic (including neck lymph nodes) measurable disease
• •* At least 20 mm by conventional techniques or at least 10 mm by spiral CT scan
• •* The following are not considered measurable disease:
• •* Leptomeningeal disease
• •* Ascites
• •* Pleural/pericardial effusion
• •* Lymphangitis cutis/pulmonis
• •* Abdominal masses that are not confirmed and followed by imaging techniques
• •* Cystic lesions
• •* Tumor lesions within a previously irradiated area
• •* Elevated serum thyroglobulin levels indicating the presence of metastatic disease
• •* Must have negative thyroglobulin antibodies
• •Must have progressive disease within the past year, defined by at least 1 of the following:
• •* At least 20% increase in serum thyroglobulin levels
• •* At least 20% increase in the sum of the longest diameter of measurable lesions
• •* Appearance of at least 1 new lesion
• •Failed or ineligible for standard therapy with iodine I 131 and/or surgery
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 1 year
• •Hematopoietic
• •Absolute neutrophil count at least 1,000/mm\^3
• •Platelet count at least 75,000/mm\^3
• •Hepatic
• •Bilirubin no greater than 2.0 mg/dL
• •AST/ALT no greater than 2 times upper limit of normal
• •Renal
• •Creatinine no greater than 2.0 mg/dL
• •Cardiovascular
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No uncontrolled cardiac arrhythmia
• •Gastrointestinal
• •No prior symptomatic or complicated peptic ulcer disease by endoscopy within the past 6 months, defined by any of the following conditions:
• •* Active gastric or duodenal ulcer
• •* Gastric or duodenal perforation
• •* Upper gastrointestinal bleeding
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •No prior allergic reaction to celecoxib or sulfonamides
• •No prior urticaria, asthma, or allergic reaction to aspirin or other nonsteroidal anti-inflammatory agents
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •No other uncontrolled concurrent illness that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •More than 1 month since prior systemic chemotherapy
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •See Disease Characteristics
• •More than 3 months since prior external beam radiotherapy (unless an indicator lesion is outside the radiation field)
• •More than 6 months since prior iodine I 131 therapy
• •Surgery
• •See Disease Characteristics
• •More than 1 month since prior surgery
• •Other
• •More than 2 weeks since prior conventional doses of celecoxib or rofecoxib for osteoarthritis, rheumatoid arthritis, or dysmenorrhea
• •No concurrent combination antiretroviral therapy for HIV-positive patients
• •No other concurrent investigational agents
• •No concurrent chronic (more than 1 week of therapy) fluconazole therapy
• •Concurrent oral or IV bisphosphonates for bony metastases are allowed
• •Concurrent low-dose aspirin (no greater than 325 mg/day) for cardiovascular disease is allowed